Upcoming event

Tags

3D reconstruction, Article of the Month, Artificial intelligence, ASCO GU22, ASCO21, AUA21, augmented reality, biomarkers, Cabozantinib, Carcinoma, CheckMate-214, CheckMate-9ER, Checkpoint Inhibitor, Chronic kidney disease, clampless surgery, Cryosurgery, cystic masses, EAU, EAU21, EAU22, EMUC21, EMUC22, enucleoresection, ERUS 2026, ERUS22, ESMO21, ESMO25, expert interview, Frail patient​, Glomerular filtration rate, Guidelines, histology, imaging, IMDC risk model, International Metastatic Renal Cell Carcinoma Database Consortium, intraoperative cyst rupture, intraoperative ultrasound, Kidney cancer, Laparoscopy, localised renal cell carcinoma, Lymph node metastases, Lymph nodes, Metastasectomy, metastatic disease, metastatic RCC, Mortality, neoadjuvant immunotherapy, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, Overall survival, papillary tumour, Partial nephrectomy, precision therapy, Prognostication, Radical nephrectomy, Radical surgery, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, risk stratification, robot-assisted partial nephrectomy, Robotic, robotic partial nephrectomy, Robotic prostatectomy, Robotic surgery, selective clamping, stereotactic body radiation therapy, Survival outcome, Suture, sutureless partial nephrectomy, Targeted therapies, Treatment response, tumour enucleation, tumour genomics, tumour pseudocapsule rupture, Urological surgery, UROonco2025, UROonco24, UROonco25, UROwebinar, Webinar, zero-ischaemia surgery
Show all

Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study

Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC)

Local recurrence following resection of intermediate-high risk nonmetastatic renal cell carcinoma: an anatomical classification and analysis of the ASSURE (ECOG-ACRIN E2805) adjuvant trial

Journal of Urology, October 2020

Cryoablation predisposes to higher cancer specific mortality relative to partial nephrectomy in patients with nonmetastatic pT1b kidney cancer

The Journal of Urology, Volume 202, Issue 6, December 2020

Nephrectomy after complete response to immune checkpoint inhibitors for metastatic Renal Cell Carcinoma (mRCC): A new surgical challenge?

The IRON study: Investigation of Robot-assisted versus Open Nephron-sparing surgery

Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry

Novel classification model of tumour shape irregularity: Significance for predicting potential oncologic risks in clinically localised renal cell carcinoma

Benchmarking current nephrectomy practice in malignant disease in England: An analysis of the BAUS complex operation registry

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

The Lancet Oncology, Volume 21, Issue 1, January 2020, Pages 95-104

Beyond the limits of ultrasound: Three dimensional augmented reality robot assisted partial nephrectomy (3D AR-RAPN) for complex renal masses

Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: A new surgical challenge?

European Urology, January 2020

PreviousNext